ストックスクリーナーアプリを入手
49.19
1.15%
0.56
アフターアワーズ：
50.00
0.81
+1.65%
Supernus Pharmaceuticals Inc (SUPN) 最新ニュース
Supernus Pharmaceuticals Q1 Earnings Call Highlights - Yahoo Finance
Supernus outlines $840M-$870M 2026 revenue outlook as ONAPGO second-supplier filing targeted for Q3 - MSN
Supernus (SUPN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Supernus (SUPN) Q1 2026 Earnings Transcript - The Globe and Mail
Supernus Pharmaceuticals Q1 2026 Earnings Call Transcript - MarketBeat
Supernus Pharmaceuticals (SUPN) Beats Q1 Earnings and Revenue Estimates - Yahoo Finance
Supernus Pharmaceuticals (SUPN) Stock Rises on Q1 2026 Earnings - Quiver Quantitative
SUPERNUS PHARMACEUTICALS ($SUPN) Releases Q1 2026 Earnings, Stock Rises - Quiver Quantitative
Four newer Supernus drugs bring in $149.1M as 2026 outlook holds - Stock Titan
[10-Q] SUPERNUS PHARMACEUTICALS, INC. Quarterly Earnings Report - Stock Titan
Supernus Pharmaceuticals’s (NASDAQ:SUPN) Q1 CY2026 Sales Beat Estimates - Yahoo Finance
Supernus Announces First Quarter 2026 Financial Results - GlobeNewswire
Supernus faces earnings test as Onapgo launch gains traction - Investing.com
Supernus Pharmaceuticals Q1 2026 earnings preview - MSN
How Supernus Pharmaceuticals Inc. (SUPN) Affects Rotational Strategy Timing - Stock Traders Daily
Supernus Pharmaceuticals Earnings: What To Look For From SUPN - Yahoo Finance
[ARS] SUPERNUS PHARMACEUTICALS, INC. SEC Filing - Stock Titan
Supernus (NASDAQ: SUPN) sets 2026 virtual meeting on directors, pay and equity plan - Stock Titan
Vanguard (NASDAQ: SUPN) owns 2.9M Supernus shares, 5.03% stake - Stock Titan
Piper Sandler Upgrades Supernus Pharmaceuticals (SUPN) - MSN
Supernus finalizes $350M asset acquisition of Navitor’s SPN-820 - MSN
Vanguard Portfolio Management (NASDAQ: SUPN) holds 3.26M shares, 5.66% - Stock Titan
Supernus Signals Shift on Nasdaq Chart After Results - Kalkine Media
Branded Pharmaceuticals Stocks Q4 Results: Benchmarking Supernus Pharmaceuticals (NASDAQ:SUPN) - Yahoo Finance
Pharmaceutical Company Sued For Antitrust Appeals No D&O Coverage Ruling - Mealey's
BofA cuts Supernus Pharmaceuticals stock price target on costs By Investing.com - Investing.com Canada
A Look At Supernus Pharmaceuticals (SUPN) Valuation After Strong Recent Shareholder Returns - simplywall.st
Biogen Q1 Earnings: Can New Launches Offset Declining MS Franchise? - TradingView
(SUPN) and the Role of Price-Sensitive Allocations - Stock Traders Daily
SUPN (Supernus Pharmaceuticals Inc.) delivers 142 percent Q4 2025 EPS surprise, shares rise 4.41 percent today.Shared Buy Zones - Cổng thông tin điện tử Tỉnh Sơn La
Supernus (SUPN) sets May 5 call to discuss Q1 2026 results - Stock Titan
Supernus will detail first-quarter results after markets close May 5 - Stock Titan
Supernus Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference ... - Caledonian Record
Supernus Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 5, 2026 - GlobeNewswire
Supernus Pharmaceuticals (SUPN) Stock: Worth Holding? (Bearish Sentiment) 2026-04-20Community Momentum Stocks - Cổng thông tin điện tử tỉnh Tây Ninh
Latest SUPN NewsSupernus Announces First Quarter 2020 Finan... - Stock Titan
Supernus Pharmaceuticals (SUPN) Stock DCF Valuation (Creeps Higher) 2026-04-18Sector Leader - Xã Thanh Hà
Revvity, Bio-Techne, Corcept, Supernus Pharmaceuticals, and Phibro Animal Health Shares Skyrocket, What You Need To Know - Yahoo Finance
Supernus Pharmaceuticals (SUPN) Stock: Trend Direction (Trend Strengthens) 2026-04-18Community Buy Signals - Cổng thông tin điện tử tỉnh Tây Ninh
Q4 2025 Supernus Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
MACD Signal: Is Supernus Pharmaceuticals Inc part of any major index2026 Year in Review & Free AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Tudor Investment Corp ET AL Invests $1.43 Million in Supernus Pharmaceuticals - National Today
Responsive Playbooks and the SUPN Inflection - Stock Traders Daily
Supernus Pharmaceuticals, Inc. (SUPN) Stock forecasts - Yahoo Finance UK
Supernus Pharmaceuticals (SUPN) Enters $350M Asset Purchase Agre - GuruFocus
Supernus Pharmaceuticals Acquires NV-5138 (SPN-820) Compound from Navitor Pharmaceuticals in Asset Purchase Agreement - Minichart
0.67%
2.13%
大文字化:
|
ボリューム (24 時間):